1804 The driver landscape of breast cancer metastasis and relapse von Yates, L, Knappskog, S, Martincorena, I, Gerstung, M, Stratton, M, Lonning, P.E, Campbell, P

Volltext

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? von Lønning, P.E

Volltext

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling von Chekenya, M, Krakstad, C, Svendsen, A, Netland, I A, Staalesen, V, Tysnes, B B, Selheim, F, Wang, J, Sakariassen, P Ø, Sandal, T, Lønning, P E, Flatmark, T, Enger, P Ø, Bjerkvig, R, Sioud, M, Stallcup, W B

Volltext

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers von Lønning, P E, Knappskog, S

Volltext

503P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway von Helland, A., Tasken, K., Russnes, H.E.G., Fagereng, L., Blix, E.S., Brabrand, S., Donnem, T., Flobak, Å., Gjertsen, B.T., Haug, A., Hovland, R., Inpred, G., Lonning, P.E., Niehusmann, P., Puco, K., Samdal, E.S., Smeland, S.

Volltext

1315O Key learnings from building: A precision cancer medicine implementation initiative for Norway von Tasken, K., Russnes, H.G., Aas, E., Bjorge, L., Blix, E.S., Enerly, E., Fagereng, L., Flobak, Å., Gilje, B., Gjertsen, B.T., Guren, T.K.K., Heix, J., Hovig, E., Hovland, R., Lonning, P.E., Mæhle, P.M., Nilsen, H.L., Thoresen, S., Smeland, S., Helland, A.

Volltext

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia von Ånensen, N, Hjelle, S M, Van Belle, W, Haaland, I, Silden, E, Bourdon, J-C, Hovland, R, Taskén, K, Knappskog, S, Lønning, P E, Bruserud, Ø, Gjertsen, B T

Volltext

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer von Eikesdal, H.P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E.S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., Venizelos, A., Minsaas, L., Leirvaag, B., Gudlaugsson, E.G., Vintermyr, O.K., Aase, H.S., Aas, T., Balmaña, J., Serra, V., Janssen, E.A.M., Knappskog, S., Lønning, P.E.

Volltext

Germline SNP analysis as a biomarker for the prediction response to therapy in breast cancer von Kristensen, V, Nordgard, S.H, Naume, B, Lonning, P.E, Borresen-Dale, A.L

Volltext

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum von Lønning, P.E.

Volltext

86 INVITED Biological lessons from adjuvant therapy von Lønning, P.E

Volltext

Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications von Kristensen, Vessela N, Soerlie, Therese, Geisler, Jurgen, Langeroed, Anita, Yoshimura, Noriko, Kaaresen, Rolf, Harada, Nobuhiro, Loenning, P E, Boerresen-Dale, Anne-Lise

Volltext

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status von Lønning, P.E., Helle, H., Duong, N.K., Ekse, D., Aas, T., Geisler, J.

Volltext

Breast cancer prognostication and prediction: are we making progress? von Lønning, P. E.

Volltext

183PD - Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer von Lønning, P.E., Clausen, C., Blix, E.S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E.A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Eikesdal, H.P.

Volltext

184PD - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer von Eikesdal, H.P., Yndestad, S., Blix, E.S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E.A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Lønning, P.E.

Volltext

Neoadjuvant olaparib monotherapy in primary triple negative breast cancer von Eikesdal, H.P., Yndestad, S., Blix, E.S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E.A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Lønning, P.E.

Volltext

Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer von Lønning, P.E., Clausen, C., Blix, E.S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E.A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Eikesdal, H.P.

Volltext

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for... von Lønning, P.E.

Volltext

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study von Geisler, J., Lønning, P.E., Krag, L.E., Løkkevik, E., Risberg, T., Hagen, A.I., Schlichting, E., Lien, E.A., Øfjord, E.S., Eide, G.E., Polli, A., di Salle, E., Paolini, J.

Volltext